Online inquiry

IVTScrip™ mRNA-Anti-CD3E&MS4A1, GEN3013(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7667MR)

This product GTTS-WQ7667MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD3E&MS4A1 gene. The antibody can be applied in B-cell malignancies research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens; Chimeric
RefSeq NM_000733.4; NM_021950.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 931
UniProt ID P07766; P11836
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&MS4A1, GEN3013(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ7667MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ304MR IVTScrip™ mRNA-Anti-IGF1R, 19D12(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA 19D12
GTTS-WQ12264MR IVTScrip™ mRNA-Anti-IL6R, MRA(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MRA
GTTS-WQ12958MR IVTScrip™ mRNA-Anti-TNFRSF12A, PDL 192(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PDL 192
GTTS-WQ14530MR IVTScrip™ mRNA-Anti-IL6R, SA-237(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA SA-237
GTTS-WQ11593MR IVTScrip™ mRNA-Anti-ERBB2, MGAH-22(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MGAH-22
GTTS-WQ2494MR IVTScrip™ mRNA-Anti-CD3E&FOLH1, AMG 212(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 212
GTTS-WQ245MR IVTScrip™ mRNA-Anti-B4GALNT1, 14.18 mAb(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA 14.18 mAb
GTTS-WQ311MR IVTScrip™ mRNA-Anti-IGF1R, 19D12(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA 19D12
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW